查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040701

骨關節炎注射藥物市場規模、佔有率和趨勢分析報告：按注射藥物類型、解剖部位、最終用途和細分市場預測（2026-2033 年）

Osteoarthritis Injectable Market Size, Share & Trends Analysis Report By Injection Type (Hyaluronic Acid Injections, Corticosteroids Injections), By Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), By End Use, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 137 Pages | 商品交期: 2-10個工作天內

價格

骨關節炎注射藥物概述

2025 年全球注射用骨關節炎治療市場價值 81.8 億美元，預計到 2033 年將達到 141.6 億美元，2026 年至 2033 年的複合年成長率為 7.17%。

這一成長主要由骨關節炎（OA）的日益普遍（尤其是在老年人中）以及人們對微創治療方法的認知不斷提高所驅動。

此外，生物製藥和新一代注射的進步，以及關鍵地區有利的醫保報銷政策，預計將在預測期內進一步推動市場擴張。向緻密的關節內組織輸送藥物的挑戰，正在加速骨關節炎注射療法的研發活動。各公司正專注於關節內生物製藥和緩解疾病劑。 Biosplice Therapeutics公司的loresivivint和OrthoTrophix公司的TPX-100等候選藥物，正是持續創新的例證。例如，Biosplice Therapeutics公司於2026年1月向美國FDA提交了loresivivint的新藥認證（NDA），這是一種用於治療膝骨關節炎的關節內注射劑。該藥物在III期臨床試驗中顯示出緩解疼痛和改善功能的良好效果。

同樣，OrthoTrophix公司於2026年3月完成了TPX-100 IIb期臨床試驗的患者招募，鞏固了其在骨關節炎軟骨再生標靶緩解疾病關節內療法研發領域的地位。隨著精準醫療的日益普及，注射型骨關節炎（OA）市場格局正在重塑，對患者特異性生物製藥和再生醫學的關注度也隨之提升。哥倫比亞大學一項關於軟骨再生幹細胞的研究凸顯了基於精準醫療的注射療法在疾病早期階段的巨大潛力。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 全球骨關節炎注射藥物市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 全球骨關節炎注射劑市場分析工具

第4章 全球骨關節炎注射藥物市場：按注射藥物類型分類的估算與趨勢分析

  • 按注射劑類型分類的市場佔有率（2025 年和 2033 年）
  • 全球骨關節炎注射藥物市場：按注射藥物類型分類的展望
  • 市場規模、預測與趨勢分析，2021-2033年
    • 玻尿酸注射
    • 皮質類固醇注射
    • 富血小板血漿（PRP）注射
    • 胎盤組織基質（PTM）注射
    • 乙醯水楊酸（ASA）注射液
    • 其他

第5章 全球注射型骨關節炎治療市場：依解剖部位分類的估計與趨勢分析

  • 按解剖區域分類的市場佔有率（2025 年和 2033 年）
  • 全球注射式骨關節炎治療市場：基於解剖部位的展望
  • 市場規模、預測與趨勢分析，2021-2033年
    • 膝關節骨關節炎
    • 髖關節骨關節炎
    • 手腕關節骨關節炎
    • 其他

第6章 全球骨關節炎注射藥物市場：依最終用途分類的估算與趨勢分析

  • 按最終用途分類的市場佔有率（2025 年和 2033 年）
  • 全球注射式骨關節炎治療市場：依最終用途分類，展望
  • 市場規模、預測與趨勢分析，2021-2033年
    • 醫院藥房
    • 零售藥房
    • 其他

第7章 全球骨關節炎注射藥物市場：區域估算與趨勢分析

  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司和競爭對手的分類
  • 供應商情況
    • 主要銷售代理商和通路夥伴名單
    • Key customers
    • Key company market share analysis, 2025
    • Anika Therapeutics, Inc.
    • Bioventus.
    • Ferring Pharmaceuticals Inc.
    • Sanofi SA
    • Flexion Therapeutics, Inc.
    • Zimmer Biomet
    • Arthrex, Inc.
    • Royal Biologics
    • Teva Pharmaceutical Industries Ltd.

第9章：總結與分析師觀點

Product Code: GVR-4-68040-291-5

Osteoarthritis Injectable Market Summary

The global osteoarthritis injectable market size was valued at USD 8.18 billion in 2025 and is projected to reach USD 14.16 billion by 2033, growing at a CAGR of 7.17% from 2026 to 2033. This growth is primarily driven by the increasing prevalence of osteoarthritis (OA), particularly among the aging population, as well as rising awareness of minimally invasive treatment options.

Additionally, advancements in biologic therapies and next-generation injectable, along with supportive reimbursement policies in key regions, are expected to further propel market expansion over the forecast period. R&D activities in injectable osteoarthritis therapies are accelerating due to challenges in delivering drugs into dense joint tissues. Companies are focusing on intra-articular biologics and disease-modifying agents. Candidates like lorecivivint from Biosplice Therapeutics and TPX-100 from OrthoTrophix highlight ongoing innovation. For instance, in January 2026, Biosplice Therapeutics submitted a New Drug Application (NDA) to the U.S. FDA for lorecivivint, an intra-articular injection for knee osteoarthritis, which showed promising Phase III results for pain reduction and functional improvement.

Similarly, in March 2026, OrthoTrophix advanced its Phase 2b clinical trial of TPX-100 by completing patient enrollment, reinforcing its position in developing disease-modifying intra-articular therapies targeting cartilage regeneration in osteoarthritis. The growing emphasis on personalized medicine is reshaping the OA injectable market, with a greater focus on patient-specific biologics and regenerative therapies. Research from Columbia University on cartilage-regenerating stem cells highlights the potential for precision-based injectable treatments targeting early-stage disease progression.

Global Osteoarthritis Injectable Market Repoprt Segmentation

This report forecasts revenue growth at, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global osteoarthritis injectable market report on the basis of injection type, anatomy, end use, and region:

  • Injection Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Hyaluronic Acid Injections
  • Corticosteroid Injections
  • Platelet-rich Plasma (PRP) Injections
  • Placental Tissue Matrix (PTM) Injections
  • Acetylsalicylic Acid (ASA) Injections
  • Others
  • Anatomy Outlook (Revenue, USD Million, 2021 - 2033)
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Injection Type
    • 1.2.2. Anatomy
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Injection Type
    • 2.2.2. End Use
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Global Osteoarthritis Injectable Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of osteoarthritis
      • 3.2.1.2. Growing geriatric population susceptible to osteoarthritis
      • 3.2.1.3. Increase in R&D activities for injectable drug development
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Adoption of other treatment options
      • 3.2.2.2. High cost of treatment
  • 3.3. Global Osteoarthritis Injectable Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social Landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal Landscape
    • 3.3.3. Pricing Analysis

Chapter 4. Global Osteoarthritis Injectable Market: Injection Type Estimates & Trend Analysis

  • 4.1. Injection Type Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Osteoarthritis Injectable Market by Injection Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Hyaluronic Acid Injections
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.4.2. Corticosteroid Injections
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.4.3. Platelet-rich Plasma (PRP) Injections
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.4.4. Placental Tissue Matrix (PTM) Injections
      • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.4.5. Acetylsalicylic Acid (ASA) Injections
      • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.4.6. Others
      • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Global Osteoarthritis Injectable Market: Anatomy Estimates & Trend Analysis

  • 5.1. Anatomy Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Osteoarthritis Injectable Market by Anatomy Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Knee Osteoarthritis
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 5.4.2. Hip Osteoarthritis
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 5.4.3. Hand Osteoarthritis
      • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 5.4.4. Others
      • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 6. Global Osteoarthritis Injectable Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Osteoarthritis Injectable Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Hospital Pharmacies
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 6.4.2. Retail Pharmacies
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 7. Global Osteoarthritis Injectable Market: Regional Estimates & Trend Analysis by

  • 7.1. Regional Market Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Billion)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2025
    • 8.3.4. Anika Therapeutics, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Injection Type benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Bioventus.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Injection Type benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Ferring Pharmaceuticals Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Injection Type benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Sanofi S.A.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Injection Type benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Flexion Therapeutics, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Injection Type benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Zimmer Biomet
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Injection Type benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Arthrex, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Injection Type benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Royal Biologics
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Injection Type benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Teva Pharmaceutical Industries Ltd.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Injection Type benchmarking
      • 8.3.12.4. Strategic initiatives

Chapter 9. Conclusion and Analyst Perspective

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 North America Osteoarthritis injectable Market, by country, 2021 - 2033 (USD Billion)
  • Table 4 North America Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 5 North America Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 6 North America Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 7 U.S. Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 8 U.S. Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 9 U.S. Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 10 Canada Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 11 Canada Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 12 Canada Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 13 Mexico Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 14 Mexico Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 15 Mexico Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 16 Europe Osteoarthritis injectable Market, by country, 2021 - 2033 (USD Billion)
  • Table 17 Europe Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 18 Europe Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 19 Europe Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 20 Germany Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 21 Germany Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 22 Germany Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 23 UK Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 24 UK Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 25 UK Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 26 France Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 27 France Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 28 France Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 29 Italy Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 30 Italy Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 31 Italy Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 32 Spain Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 33 Spain Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 34 Spain Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 35 Denmark Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 36 Denmark Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 37 Denmark Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 38 Sweden Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 39 Sweden Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 40 Sweden Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 41 Norway Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 42 Norway Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 43 Norway Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 44 Asia Pacific Osteoarthritis injectable Market, by country, 2021 - 2033 (USD Billion)
  • Table 45 Asia Pacific Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 46 Asia Pacific Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 47 Asia Pacific Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 48 Japan Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 49 Japan Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 50 Japan Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 51 China Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 52 China Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 53 China Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 54 India Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 55 India Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 56 India Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 57 Australia Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 58 Australia Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 59 Australia Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 60 South Korea Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 61 South Korea Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 62 South Korea Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 63 Thailand Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 64 Thailand Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 65 Thailand Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 66 Latin America Osteoarthritis injectable Market, by country, 2021 - 2033 (USD Billion)
  • Table 67 Latin America Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 68 Latin America Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 69 Latin America Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 70 Brazil Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 71 Brazil Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 72 Brazil Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 73 Argentina Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 74 Argentina Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 75 Argentina Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 76 MEA Osteoarthritis injectable Market, by country, 2021 - 2033 (USD Billion)
  • Table 77 MEA Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 78 MEA Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 79 MEA Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 80 South Africa Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 81 South Africa Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 82 South Africa Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 83 Saudi Arabia Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 84 Saudi Arabia Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 85 Saudi Arabia Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 86 UAE Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 87 UAE Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 88 UAE Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 89 Kuwait Osteoarthritis injectable Market, by Injection Type, 2021 - 2033 (USD Billion)
  • Table 90 Kuwait Osteoarthritis injectable Market, by Anatomy, 2021 - 2033 (USD Billion)
  • Table 91 Kuwait Osteoarthritis injectable Market, by End Use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Global osteoarthritis injectable market: market outlook
  • Fig. 9 Global Osteoarthritis Injectable competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Global osteoarthritis injectable market driver impact
  • Fig. 15 Global osteoarthritis injectable market restraint impact
  • Fig. 16 Global osteoarthritis injectable market strategic initiatives analysis
  • Fig. 17 Global osteoarthritis injectable market: Injection Type movement analysis
  • Fig. 18 Global osteoarthritis injectable market: Injection Type outlook and key takeaways
  • Fig. 19 Hyaluronic Acid Injections market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig. 20 Corticosteroid Injections market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig. 21 Platelet-rich Plasma (PRP) Injections market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig. 22 Placental Tissue Matrix (PTM) Injections market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig. 23 Acetylsalicylic Acid (ASA) Injections market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig. 24 Others market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig. 25 Global osteoarthritis injectable market: Anatomy movement analysis
  • Fig. 26 Global osteoarthritis injectable market: Anatomy outlook and key takeaways
  • Fig. 27 Knee Osteoarthritis market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 28 Hip Osteoarthritis market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 29 Hand Osteoarthritis market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 30 Others market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 31 Global osteoarthritis injectable market: End Use movement analysis
  • Fig. 32 Global osteoarthritis injectable market: End Use outlook and key takeaways
  • Fig. 33 Hospital Pharmacies market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 34 Retail Pharmacies market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 36 Market share of key market players- Global osteoarthritis injectable market
  • Fig. 37 North America market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 38 U.S. market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 39 Canada market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 40 Mexico market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 41 Europe market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 42 UK market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 43 Germany market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 44 Spain market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 45 France market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 46 Italy market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 47 Sweden market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 48 Denmark market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 49 Norway market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 50 Asia Pacific market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 51 China market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 52 Japan market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 53 India market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 54 Australia market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 55 South Korea market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 56 Thailand market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 57 Latin America market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 58 Brazil market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 59 Argentina market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 60 Middle East and Africa market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 61 South Africa market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 62 Saudi Arabia market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 63 UAE market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 64 Kuwait market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)